Exon 20 insertion mutations are predictive of a poor response to approved EGFR TKI therapies, but little data exists regarding responsiveness to immunotherapy for these patients. A 2018 ASCO presentation (1) showed better efficacy with ICIs in patients with exon 20 insertions compared to patients wi...